Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC

Project Information

EPIC-CROWN-2

Grant agreement ID: 101046084

DOI 10.3030/101046084

Project closed

EC signature date 11 November 2021

Start date 1 June 2021

End date 30 November 2023

Funded under

• Health

Total cost € 9 182 634,25

EU contribution € 9 070 134,25

Coordinated by

FABENTECH
France

Deliverables

Documents, reports (9)

Steering committee presentation
Dissemination plan
Specific monitoring of impacts
Gender Equality Plan
Assessment of the administration route providing higher FBR-002 efficacy in an animal model
Project handbook
FBR-002 Neutralizing potency against VOC (NT50 &PRNT50)

FBR002 Neutralizing potency against VOC NT50 PRNT50

Collection of clinical isolates of SARS-CoV-2 VOCs

Collection of clinical isolates of SARSCoV2 VOCs

Digital communication tools

Publications

Other (1)

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

Author(s): Joanna Luczkowiak, Pauline Radreau, Ludovic Nguyen, Nuria Labiod, Fátima Lasala, Francisco Veas, Cécile Hélène Herbreteau, and Rafael Delgado
Published in: The Journal of Infectious Diseases, Issue 227 (1), 2022
Publisher: Infectious Diseases Society of America
DOI: 10.1093/infdis/jiac331